Other Products → LIPOLYSIS
MOUNJARO
Tirzepatide (2.5mg / 5mg / 7.5mg / 10mg)
MOUNJARO® is a once-weekly prescription injection containing tirzepatide, a dual GIP and GLP-1 receptor agonist developed by Eli Lilly for type 2 diabetes and approved indications.
Categories
+
Effects
+
Helps improve glycemic control by enhancing insulin secretion and reducing glucagon when glucose is elevated. It also regulates appetite and caloric intake.
SPEC
+
4 Pens
Content
+
Active Ingredient: Tirzepatide
Available Strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg / 0.5 mL currently supplied in Korea
Once-weekly subcutaneous injection
Single-dose pre-filled pen
4 pens per box
Price
+
Pricing may vary depending on the order quantity and business requirements. Our sales team is ready to assist you with current pricing and availability. Feel free to contact us anytime.
